NEUROPROTECTION INFLUENCE ON COURSE OF CEREBRAL STROKE

• Published in: Medical Council no. 11; pp. 26 - 31
• Main Authors: BELSKAYA, G. N., PIZOVA, N. V., SOKOLOV, M. A., IZMALOV, I. A.
• Format: Journal Article
• Language: English
• Published: Remedium Group LLC 01.12.2016
• Subjects: acute disturbance of cerebral blood circulation; cellex
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2016-11-26-31

Objective. To evaluate clinical efficacy and tolerability of cellex in the treatment of patients with cerebral stroke. Material and methods. In 2 multi-center researches of Russian clinical sites were involved 178 and 480 patients with acute disturbance of cerebral blood circulation (ADCBC), respectively. The first research was comparative with open inclusion of 146 (82%) patients with ischemic stroke and 32 (18%) – with hemorrhagic stroke at the age of 35-80. In the second research, which was doubleblind, placebo controlled, randomized, patients with ischemic stroke got Cellex or placebo during the standard base therapy. Results and conclusion. Thus, a statistically significant (р < 0,05) advance of paresis regression (by NIHSS scale) was noted in the Cellex group by the 6th day of observation as compared to the control group. Evaluation of therapy results in patients with total aphasia showed that the value of the mean Questionnaire speech values after Cellex administration (р < 0,05) exceeded the respective control group level by 3 times. In patients who administered Cellex the IPC test result increased by 24%, whereas in the control group – only by 14.8% (p < 0,01). The research showed that in group of the patients under prescription of Cellex marked authentically better result with regress of movement, visual, speech and cognitive disorders.